Innovent Biologics, Inc.: Carcinoma, Non-Small-Cell Lung trials
The registry lists 11 Carcinoma, Non-Small-Cell Lung studies with Innovent Biologics, Inc. as lead sponsor. 3 are open to participants now and 2 have results posted.
Phase 1 5Phase 2 1Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid TumorsRecruitingNCT07589205Phase 1
- Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain MetastasesRecruitingNCT07008287
- Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C MutationRecruitingNCT05504278Phase 1
- Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLCCompletedNCT03629925Phase 3Results posted
- Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLCCompletedNCT02954172Phase 3Results posted
- The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)TerminatedNCT05849246Phase 2
- IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)CompletedNCT05118334Phase 1
- Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerActive, not recruitingNCT05116462Phase 3
- Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung CancerTerminatedNCT05088967Phase 1
- A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC PatientsCompletedNCT04177290Phase 1
- Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment FailureCompletedNCT03802240Phase 3